Retention processed placental membrane versus standard of care in treating diabetic foot ulcers

Sep 30, 2024
Wendy W. Weston
Wendy W. Weston
Retention processed placental membrane versus standard of care in treating diabetic foot ulcers

Diabetic foot ulcers (DFUs) are a severe complication for diabetic patients, significantly impacting patient quality of life and healthcare system efficiency. Traditional standard of care (SOC) treatments are inadequate for many patients, necessitating the use of advanced wound care products, such as human placental membranes.

Abstract

Diabetic foot ulcers (DFUs) are a severe complication for diabetic patients, significantly impacting patient quality of life and healthcare system efficiency. Traditional standard of care (SOC) treatments are inadequate for many patients, necessitating the use of advanced wound care products, such as human placental membranes. We studied a real-world population of large, hard-to-heal and complicated wounds, otherwise under-studied in the wound care literature. To this end, we conducted a retrospective cohort analysis to compare the effectiveness of a human placental amnion/chorion membrane product using retention-based processing (RE-AC) and SOC in managing chronic DFUs. During the study period of September 2021 through April 2024, we collected retrospective observational data from electronic health records of 21 patients treated with RE-AC at three outpatient wound care centres. Additionally, 21 control SOC patients were matched from a wound registry using Coarsened Exact Matching. Patients were categorized into two cohorts based on whether they received RE-AC or SOC. Key metrics included wound size progression and wound closure. The analysis employed Bayesian regression and Hurdle Gamma Analysis of Covariance models. Despite their rather large size (average of 13.8 cm2), our results indicated that RE-AC achieved almost a 10% higher expected wound closure rate compared to SOC at 12 weeks (8.53% [credible interval: 5.60%–10.7%]). Further, for wounds that did not close, REAC resulted in a 93.6% (credible interval: 147.7%–41.6) improvement in expected Percent Area Reduction over the SOC group at 12 weeks. We noted that on average, SOC wounds stalled or grew larger. In terms of a risk ratio comparing the study group with SOC, we found a 52% benefit in the RE-AC group (RR = 1.52). The findings suggest that even with larger DFUs, R-AC is superior to SOC for wound closure and expected Percent Area Reduction by 12 weeks. This benefit likely leads to reduced treatment costs, optimized

READ ENTIRE ARTICLE: https://onlinelibrary.wiley.com/doi/10.1111/iwj.70096

More Research

The Latest Research

Sep 9, 2024
David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, Paul M. Glat, Marissa J. Carter, Jason Hanft, Maria Surprenant, Adam L. Isaac, Charles M. Zelen
David G. Armstrong, Dennis P. Orgill, Robert D. Galiano, Paul M. Glat, Marissa J. Carter, Jason Hanft, Maria Surprenant, Adam L. Isaac, Charles M. Zelen

A multicentre clinical trial evaluating the outcomes of two application regimens of a unique keratin-based graft in the treatment of Wagner grade one non-healing diabetic foot ulcers

Diabetic foot complications that lead to lower extremity amputations pose a significant challenge to the entire global health system.

Jun 4, 2024
Zwelithini Tunyiswa, Robert G. Frykberg
Zwelithini Tunyiswa, Robert G. Frykberg

Assessing placental membrane treatment efficiency in diabetic foot ulcers: Processing for retention versus lamination

Diabetic foot ulcers are a severe complication in diabetic patients, significantly impact healthcare systems and patient quality of life, often leading to hospitalization and amputation.